DDInter1217 DDInter1607
Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the body. Miglitol should be taken at the start of a meal for maximal effect and the effect will depend on the amount of poly and oligosaccharides in the diet. Miglitol inhibits alpha-glucosidase, making less sugars available for digestion and reducing postprandial hyperglycemia. Unlike other drugs of the same class, miglitol is not metabolized and the unmetabolized drug is excreted by the kidneys.
Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors. It is now more commonly used as a booster of other protease inhibitors and is available in both liquid formulations and as capsules. While ritonavir is not an active antiviral agent against hepatitis C virus (HCV) infection, it is added in combination therapies indicated for the treatment of HCV infections as a booster. Ritonavir is a potent CYP3A inhibitor that increases peak and trough plasma drug concentrations of other protease inhibitors such as and overall drug exposure. American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) guidelines recommend ritonavir-boosted combination therapies as first-line therapy for HCV Genotype 1a/b and 4 treatment-naïve patients with or without cirrhosis. Ritonavir is found in a fixed-dose combination product with , , and as the FDA-approved product Viekira Pak. First approved in December 2014, Viekira Pak is indicated for the treatment of HCV genotype 1b without cirrhosis or with compensated cirrhosis, and when combined with Ribavirin for the treatment of HCV genotype 1a without cirrhosis or with compensated cirrhosis. Ritonavir is also available as a fixed-dose combination product with and as the FDA- and Health Canada-approved product Technivie. First approved in July 2015, Technivie is indicated in combination with Ribavirin for the treatment of patients with genotype 4 chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis. In Canada, ritonavir is also available as a fixed-dose combination product with , , and as the Health Canada-approved, commercially available product Holkira Pak. First approved in January 2015, Holkira Pak is indicated for the treatment of HCV genotype 1b with or without cirrhosis, and when combined with Ribavirin for the treatment of HCV genotype 1a with or without cirrhosis. The inclusion of ritonavir can select for HIV-1 protease inhibitor resistance-associated substitutions. Any HCV/HIV-1 co-infected patients treated with ritonavir-containing combination therapies should also be on a suppressive antiretroviral drug regimen to reduce the risk of HIV-1 protease inhibitor drug resistance. Ritonavir is combined with other drugs to treat coronavirus disease 2019 (COVID-19) in patients at risk for progressing into a severe form of the disease, such as [nirmatrelvir].
Miglitol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Atazanavir
Atazanavir {u} (Compound) resembles {v} (Compound) Ritonavir
Miglitol {u} (Compound) causes {v} (Side Effect) Rectal haemorrhage
Rectal haemorrhage {u} (Side Effect) is caused by {v} (Compound) Ritonavir
Miglitol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Atazanavir
Atazanavir {u} (Compound) resembles {v} (Compound) Lopinavir
Lopinavir {u} (Compound) resembles {v} (Compound) Ritonavir
Miglitol {u} (Compound) causes {v} (Side Effect) Diarrhoea
Diarrhoea {u} (Side Effect) is caused by {v} (Compound) Atazanavir
Atazanavir {u} (Compound) resembles {v} (Compound) Ritonavir
Miglitol {u} (Compound) resembles {v} (Compound) Miglustat
Miglustat {u} (Compound) causes {v} (Side Effect) Nervous system disorder
Nervous system disorder {u} (Side Effect) is caused by {v} (Compound) Ritonavir
Miglitol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Atazanavir
Atazanavir {u} (Compound) binds {v} (Gene) ABCC1
ABCC1 {u} (Gene) is bound by {v} (Compound) Ritonavir
Miglitol {u} (Compound) treats {v} (Disease) type 2 diabetes mellitus
type 2 diabetes mellitus {u} (Disease) is associated with {v} (Gene) CYP2E1
CYP2E1 {u} (Gene) is bound by {v} (Compound) Ritonavir
Miglitol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Amcinonide
Amcinonide {u} (Compound) causes {v} (Side Effect) Dermatitis contact
Dermatitis contact {u} (Side Effect) is caused by {v} (Compound) Ritonavir
Miglitol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ranitidine
Ranitidine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ritonavir
Miglitol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ranitidine
Ranitidine {u} may lead to a major life threatening interaction when taken with {v} Atazanavir
Atazanavir {u} (Compound) resembles {v} (Compound) Ritonavir
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir and Atazanavir (Compound) resembles Ritonavir (Compound)
Miglitol (Compound) causes Rectal haemorrhage (Side Effect) and Rectal haemorrhage (Side Effect) is caused by Ritonavir (Compound)
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir and Atazanavir (Compound) resembles Lopinavir (Compound) and Lopinavir (Compound) resembles Ritonavir (Compound)
Miglitol (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Atazanavir (Compound) and Atazanavir (Compound) resembles Ritonavir (Compound)
Miglitol (Compound) resembles Miglustat (Compound) and Miglustat (Compound) causes Nervous system disorder (Side Effect) and Nervous system disorder (Side Effect) is caused by Ritonavir (Compound)
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir and Atazanavir (Compound) binds ABCC1 (Gene) and ABCC1 (Gene) is bound by Ritonavir (Compound)
Miglitol (Compound) treats type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is associated with CYP2E1 (Gene) and CYP2E1 (Gene) is bound by Ritonavir (Compound)
Miglitol may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide (Compound) causes Dermatitis contact (Side Effect) and Dermatitis contact (Side Effect) is caused by Ritonavir (Compound)
Miglitol may cause a minor interaction that can limit clinical effects when taken with Ranitidine and Ranitidine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ritonavir (Compound)
Miglitol may cause a minor interaction that can limit clinical effects when taken with Ranitidine and Ranitidine may lead to a major life threatening interaction when taken with Atazanavir and Atazanavir (Compound) resembles Ritonavir (Compound)